Views & Analysis | Perspectives on pharma industry issues

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

Sales & Marketing

AI and pharma launch - Within3’s Jason Smith

Jason Smith, CTO of AI and analytics at Within3, discusses data-fuelled agile launches and smarter decision-making.

Market Access

Beyond Market Access: Why healthcare-system understanding is...

Healthcare-system literacy, and the ability to contribute to system shaping, must become part of how healthcare leaders make decisions.

Digital

Solution Spotlight: Axtria HIQ

Axtria HIQ is an agentic analytics product built specifically for pharmaceutical headquarters teams.

R&D

Digital representation of sepsis bacteria attacking heart

The hidden pandemic within the pandemic: How COVID-19 impact...

Why sepsis readiness – equipment, supply chains, surveillance, and public awareness – needs to be treated as core pandemic infrastructure.

Views & Analysis

Voices from the front line in rare disease

Online patient communities have become a vital resource for rare disease patients, and pharma is coming round to the idea of engaging with them for real-world data.

Views & Analysis

Making it as an oncology biotech in the united kingdom

Making it as an oncology biotech in the UK

We speak to R&D experts to find out how oncology biotechs can get the support they need to be successful in the competitive UK ecosystem

Views & Analysis

Rebooting the healthcare system post-COVID-19

Janssen’s Iris Zemzoum looks at seven ways the healthcare and pharma sectors need to change in the wake of COVID-19.

Sales & Marketing

AI and pharma launch - Within3’s Jason Smith

Jason Smith, CTO of AI and analytics at Within3, discusses data-fuelled agile launches and smarter decision-making.

Sales & Marketing

Your launch strategy has never met the competition

Will your launch strategy work once it has finally left the meeting room and met the competition?

Digital

Solution Spotlight: Axtria HIQ

Axtria HIQ is an agentic analytics product built specifically for pharmaceutical headquarters teams.

Digital

Beyond AI pilots: Pharma needs AI-native operating models, n...

Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.

Market Access

Beyond Market Access: Why healthcare-system understanding is...

Healthcare-system literacy, and the ability to contribute to system shaping, must become part of how healthcare leaders make decisions.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Oncology

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Patients

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Patients

Why patient safety doesn't end at approval

Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.

Taking the microbiome seriously, with Sam Possemiers

AI and pharma launch - Within3’s Jason Smith

Beyond Market Access: Why healthcare-system understanding is...

Solution Spotlight: Axtria HIQ

The hidden pandemic within the pandemic: How COVID-19 impact...

Voices from the front line in rare disease

Making it as an oncology biotech in the UK

Rebooting the healthcare system post-COVID-19

AI and pharma launch - Within3’s Jason Smith

Your launch strategy has never met the competition

Solution Spotlight: Axtria HIQ

Beyond AI pilots: Pharma needs AI-native operating models, n...

Beyond Market Access: Why healthcare-system understanding is...

Is the next generation of Chinese biotech ready to go global...

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

In vivo CAR-T can solve the delivery problem – but solid tum...

Unlocking the scalability of allogeneic CAR-T

Rare diseases, real opportunity: Why the UK’s next challenge...

Maintenance: The underexamined half of the GLP-1 story

Why patient safety doesn't end at approval

Taking the microbiome seriously, with Sam Possemiers

The hidden pandemic within the pandemic: How COVID-19 impact...

Alzheimer’s: Starting the impossible journey

Click claims FDA okay for first-in-class schizophrenia DTx

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks